Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

658 results about "Human cell" patented technology

Methods and compositions for diagnosis and treatment of metabolic disorders

Most disease-associated genetic loci map to more than one disease or trait, suggesting they act through multiple cell types and tissues giving rise to complex disease phenotypes. This pervasive pleiotropy of human diseases presents a tremendous burden on identifying mediating mechanisms and therapeutic targets. Multiple metabolic risk haplotypes are associated with risk for metabolic diseases. However, whether a haplotype actually causes a disease and the mechanisms that cause the disease are unknown. Integration of phenotypic and transcriptional profiling in primary human cells allows for functional characterization of disease-associated genetic variants. Applicants have analyzed multiple risk haplotypes and determined the function of risk haplotypes involved in causation of specific metabolic phenotypes, such as type 2 diabetes and lipodystrophy. Methods of treatments are disclosed herein.
Owner:THE BROAD INST INC +1

Engineered viral like particles (EVLPS) for the selective transduction of target cells

The present disclosure provides compositions and methods for the selective transduction and genome editing of human cells (e.g., hematopoietic stem and progenitors cells, HSPCs) using engineered viral like particles (eVLPs). Aspects of the disclosure provide eVLP compositions comprising fusion proteins comprising a targeting moiety. In some embodiments, the fusion proteins comprise a cytokine conjugated to a transmembrane protein and / or an envelope glycoprotein. In other embodiments, the fusion proteins comprise a targeting moiety domain, a stalk protein domain, a transmembrane and / or envelope glycoprotein domain. Targeted-eVLP architectures comprising various targeting domains, stalk domains, transmembrane domains, and envelope glycoproteins are also provided herein. Other aspects of the disclosure provide eVLP compositions comprising envelope glycoproteins comprising non-natural sugars and methods of conjugating said eVLPs to various targeting moieties using bio-orthogonal click chemistry. Polynucleotides, vectors, cells, and kits useful for producing the articles, and performing the methods, described herein are also provided.
Owner:THE BROAD INST INC +1

Anti-NPC VHH antibodies and methods for their stabilization

The present invention relates to VHH antibodies that specifically bind to components of nuclear pore complexes of human cells and other species. Further, the present invention relates to the labelling of VHH antibodies through maleimide chemistry and ectopic cysteine residues. Further, the present invention relates to a method for forming a stabilizing, structural disulfide bond in initially reduced VHH antibodies.
Owner:MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN EV

Methods and compositions for prime editing RNA

The present disclosure provides compositions and methods for the targeted modification of RNA molecules by RNA prime editing. The compositions and methods may be conducted invitro or in vivo within cells (e.g., human cells) for the therapeutic correction of disease-causing mutations and / or installation of motifs or mutations in RNA molecules of interest as a tool for scientific research. The disclosure provides compositions and methods for conducting RNA prime editing of a target RNA molecule (e.g., an RNA transcript) that enables the incorporation of one or more nucleotide changes and / or targeted mutagenesis of a target RNA molecule. The nucleotide change can include a single-nucleotide change, an insertion of one or more nucleotides, or a deletion of one or more nucleotides. More in particular, the disclosure provides a variety of configurations of the RNA prime editors each comprising a nucleic acid programmable RNA binding proteins (napRNAbp), such as Cas13, and an RNA-dependent RNA polymerase (RDRP), which are provided as fusion proteins or which can be separately provided in trans. The RNA prime editors are guided to a target RNA site by a guide RNA, which can be a rpegRNA that includes a template region for the synthesis of an RNA sequence to be installed on the RNA molecule attached to an available 3′ terminus. In others embodiments, the RNA template can be provided in trans.
Owner:THE BROAD INST INC +1

Monoclonal antibody against human carbohydrate antigen CA125 and application thereof

The invention belongs to the technical field of antibody preparation, and particularly relates to an anti-human carbohydrate antigen CA125 monoclonal antibody and application thereof. The amino acid sequences of CDR1-3 on a light chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.3-5, and the amino acid sequences of CDR1-3 on a heavy chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.8-10. The monoclonal antibody provided by the invention can specifically recognize and bind to a natural carbohydrate antigen CA125 expressed by human cells or tissues, has good affinity and relatively high sensitivity of binding of the antibody and the antigen, has strong anti-interference ability to complex non-target protein components in the cells / tissues, is beneficial to significantly improving the accuracy and reliability of immunodetection of human CA125 protein, and has good application prospects. The method is suitable for high-specificity, high-sensitivity and high-reliability detection of the human CA125 protein, and has good applicability in a plurality of detection systems such as immunoblotting, immunoprecipitation, immunohistochemistry and the like.
Owner:WUHAN AIBO TAIKE BIOTECH CO LTD

Grass carp-derived U6 promoter and application thereof

The invention provides a grass carp sourced U6 promoter. The sequence of the grass carp sourced U6 promoter is shown as one of SEQ ID NO: 1-3. Three grass carp-derived U6 promoters are cloned, the transcriptional activity and cross-species adaptability of the three promoters are analyzed, results show that the three promoters can show transcriptional activity in fish cells and human cells, the transcriptional activity of ciU6-1 is remarkably higher than that of the other two promoters, heterologous DNA can be transcribed in various cells, and the expression of the ciU6-1 in the fish cells and the human cells is improved. And the method can be used for gene editing means based on Cas9.
Owner:INST OF AQUATIC LIFE ACAD SINICA

Taurine cross-linked salicylic acid nano-composite gel for efficient transdermal delivery and mild acne removal as well as preparation method and application of taurine cross-linked salicylic acid nano-composite gel

The invention relates to taurine cross-linked salicylic acid nano-composite gel for efficient transdermal delivery and mild acne removal as well as a preparation method and application of the taurine cross-linked salicylic acid nano-composite gel. The nano-gel comprises salicylic acid, quaternary ammonium salt-73, taurine, polyol, lipid, an emulsifier, a co-emulsifier, an antioxidant and water. Salicylic acid, quaternary ammonium salt-73 and taurine are used as functional components for removing acnes. Salicylic acid can decompose grease on the surface of the skin, so that the oil control effect is achieved, meanwhile, skin metabolism is promoted, angular suppository is loosened, pores are dredged, and acne is treated; quaternary ammonium salt-73 has extremely high antibacterial activity, especially has a remarkable antibacterial effect on propionibacterium acnes causing acnes, and can quickly and thoroughly remove the acnes by being matched with salicylic acid; taurine provides energy required by normal physiological activities of human cells, improves skin immunity, regulates skin water-oil balance and has the effects of improving skin textures, dryness, wrinkles, elasticity, sensitivity and other skin problems, meanwhile, in the using process, taurine is preferentially absorbed by the skin, so that an inclusion shell is broken, and the skin is protected. Rapid release and transdermal absorption of salicylic acid and quaternary ammonium salt-73 are promoted, irritation is reduced, and the three components act synergistically to achieve the functions of mildly, efficiently and rapidly treating acne and reconstructing skin barrier.
Owner:BEIJING PROTA BIOTECHNOLOGY GROUP CO LTD

Methods and compositions for prime editing RNA

The present disclosure provides compositions and methods for the targeted modification of RNA molecules by RNA prime editing. The compositions and methods may be conducted invitro or in vivo within cells (e.g., human cells) for the therapeutic correction of disease-causing mutations and / or installation of motifs or mutations in RNA molecules of interest as a tool for scientific research. The disclosure provides compositions and methods for conducting RNA prime editing of a target RNA molecule (e.g., an RNA transcript) that enables the incorporation of one or more nucleotide changes and / or targeted mutagenesis of a target RNA molecule. The nucleotide change can include a single-nucleotide change, an insertion of one or more nucleotides, or a deletion of one or more nucleotides. More in particular, the disclosure provides a variety of configurations of the RNA prime editors each comprising a nucleic acid programmable RNA binding proteins (napRNAbp), such as Cas13, and an RNA-dependent RNA polymerase (RDRP), which are provided as fusion proteins or which can be separately provided in trans. The RNA prime editors are guided to a target RNA site by a guide RNA, which can be a rpegRNA that includes a template region for the synthesis of an RNA sequence to be installed on the RNA molecule attached to an available 3′ terminus. In others embodiments, the RNA template can be provided in trans.
Owner:THE BROAD INST INC +1

Stabilization of therapeutic trans-splicing RNA molecules in human cells

Disclosed are compositions comprising a nucleic acid molecule. The nucleic acid molecule may encode an exonic sequence or portion thereof of a target ribonucleic acid (RNA) sequence. The nucleic acid molecule may further encode one or more stabilization domains. The one or more stabilization domains may be configured to reduce a cellular nuclease activity compared to a nucleic acid molecule that does not comprise the one or more stabilization domains.
Owner:TACIT THERAPEUTICS INC

Inhibitor of the low-density lipoprotein receptor family (LDL-r family) and / or apolipoprotein e (APOE) for use in the treatment of crimean-congo hemorrhagic fever virus (CCHFV) infection

The present invention relates to a treatment of CCHFV infection, in particular CCFHV infection. Here, the inventors showed that antibody blocking LDL-R family at the surface of human cells could reduce CCHFV infection by 80%, such inhibition only occurred when blocking was performed prior to or at the time of infection though not at later time points. Furthermore, they found that incubation of viral particles with a soluble form of LDL-R could impair CCHFV infection. They found that ApoE antibodies could block CCHFV infectivity by up to 10-fold only when the viral particles were produced in cells that express ApoE. Thus, the present invention relates to an LDL-R family and / or an ApoE inhibitor for use in the prevention and / or the treatment of CCHFV infection in subjects in need thereof.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3

Humanized immunodeficient mouse model

PendingCN120051204ACompounds screening/testingUnknown materialsImmunodeficient mouse modelHuman cell
In some aspects, the disclosure provides humanized immunodeficient mouse models that support long term transplantation and function of human T cells, natural killer cells, and bone marrow cells without the need for conditioning.
Owner:JACKSON LAB THE +1

AAV-based gene therapies for treatment of autoimmune diseases

Disclosed are AAV viral-based vector compositions useful in delivering a variety of nucleic acid segments, including those encoding therapeutic polypeptides to selected mammalian host cells for use in therapeutic autoimmune modalities, including, for example, the in vivo induction of immunological tolerance via a liver-directed AAV-based gene therapeutic regimen for treating and / or ameliorating autoimmune disorders such as multiple sclerosis. Further disclosed are nucleic acid segments encoding therapeutic polypeptides that have been codon-optimized for expression in human cells.
Owner:UNIV OF FLORIDA RESEARCH FOUNDATION INC

Novel capping enzyme

The present invention relates to an RNA capping enzyme comprising or consisting of an amino acid sequence having high identity with any of the sequences of SEQ ID NO: 1-28, which can be expressed in vitro, in human cells, in mouse cells or in yeast cells, and which has the activities of RNA 5 '-triphosphatase (RT), guanylate transferase (GT) and RNA guine-N7 methyltransferase (RNMT) at the same time. The invention also relates to a mutant obtained by carrying out substitution, addition and / or deletion of amino acid on any sequence in SEQ ID NO: 1-28, a nucleotide sequence for coding the capping enzyme and / or the mutant thereof, and an expression construct or a host cell containing the nucleotide sequence. The invention also relates to a composition comprising the capping enzyme as well as a method and a reaction system for capping RNA by using the capping enzyme, a mutant or a composition thereof.
Owner:PEKING UNIV +1

Chickpea microcarriers

This disclosure describes methods for growing cells on chickpea microcarriers as part of a process of creating a comestible food product. Generally, the disclosed method comprises adding chickpea microcarriers to cell culture media in a vessel. The chickpea microcarriers are mixed with non-human cells in the cell culture media. The chickpea microcarriers and non-human cells are mixed to adhere and grow the non-human cells on the surface of the chickpea microcarriers. After mixing, the non-human cells adhered to the surface of the chickpea microcarriers forms a textured cell tissue. The textured cell tissue can be harvested from the vessel and formed into a comestible food product.
Owner:THE UPSIDE GROUP INC

System and method for centralized fluid management and culture control

System and method for providing biocompatible, nutrient filled media to the Human Cells, Tissues, and cellular and tissue-based Products (HCT / P) while removing wastes. The present teachings provide for sensing the characteristics of the media, and modifying the characteristics when necessary. The present teachings can also provide components that can provide fluid pumping integrated with fluid gas exchange, and sensing of fluid characteristics at consistent times during the fluid flow cycle. System and method control multiple bioreactors from a centralized media reservoir, while fluidically isolating the bioreactors from cross-contamination.
Owner:DEKA PRODUCTS LP

Method and system for detecting chimeric rate of human cells based on micro haploid

The invention provides a method and a system for detecting the chimeric rate of human cells based on a micro haploid, and belongs to the technical field of chimera analysis. According to the invention, the micro haploid is innovatively adopted as a basic unit of the genetic marker, and different from the prior art in which DNA fragments containing the genetic marker are generally enriched through a multiplex PCR amplification technology, a probe targeted capture technology is introduced for enrichment; the limitation of the multiple PCR amplification technology on the number of markers and the potential influence of the PCR amplification efficiency difference on accurate quantification are effectively avoided; meanwhile, the invention further develops a special data analysis algorithm which is used for processing sequencing data and accurately calculating the chimeric rate. A verification result shows that the scheme of the invention has excellent reliability and accuracy, and the detection sensitivity reaches the highest level of similar products on the current market. Therefore, the method has a wide application prospect in the fields needing micro chimera detection, such as hematopoietic stem cell transplantation, organ transplantation and the like.
Owner:WUHAN HAIXI BIOTECHNOLOGY CO LTD

Monoclonal antibodies that bind specifically to human TRBV9

A monoclonal humanized antibody or antigen-binding fragment thereof that specifically bind to the TRBV9 family of the human T cell receptor. A nucleic acid encoding the antibody or antigen-binding fragment thereof, an expression vector, a method for preparing the antibody, and use of the antibody in treatment of diseases or disorders associated with the human T cell receptor family. The generation of antibodies that can be used for treating, in particular AS, celiac disease and malignant blood diseases, the pathogenesis of which involves the TRBV9 family TCRs.
Owner:JOINT CO BIOCAD

Monoclonal antibodies against the beta chain region of human TRBV9

The invention relates to a monoclonal humanized antibody or antigen-binding fragment thereof that specifically bind to the TRBV9 family of the human T cell receptor. The invention also relates to a nucleic acid encoding said antibody or antigen-binding fragment thereof, an expression vector, a method for preparing said antibody, and use of said antibody in treatment of diseases or disorders associated with the human T cell receptor family. The invention is directed to generation of antibodies that can be used for treating, in particular AS, celiac disease and malignant blood diseases, the pathogenesis of which involves the TRBV9 family TCRs.
Owner:JOINT CO BIOCAD

Humanized osteoporosis mouse model and construction method thereof

The invention discloses a humanized osteoporosis mouse model and a construction method thereof, and belongs to the technical field of biotechnology and animal models. The invention aims at the core defects of large species difference, insufficient humanization degree, low pathological simulation degree, unstable phenotype and the like of the existing osteoporosis model. The humanized osteoporosis mouse model is constructed through five core steps of experimental animal pretreatment, collagen-nano hydroxyapatite bionic scaffold preparation and cell pre-implantation, immune-bone metabolism double-derived system construction, progressive osteoporosis induction and model identification and verification. According to the method, double-person origination of immune and bone metabolism systems is realized for the first time, the colonization rate and survival time of human cells are greatly improved, the pathological process of clinical postmenopausal osteoporosis is accurately simulated, the phenotype of the model is stable and uniform, the reactivity matching degree with clinical drugs is high, and the method can be widely applied to research and development of anti-osteoporosis drugs and research of pathological mechanisms.
Owner:GUANGDONG LAIDI BIOMEDICAL RES INST CO LTD

Isoquinoline drugs and their use in improving or treating gastrointestinal tumors

The present application relates to the technical field of small molecule drugs, in particular to a isoquinoline drug and its application in improving or treating digestive tract tumors, and aims to provide a compound, a pharmaceutical composition containing the compound and its application in treating colorectal cancer and gastric cancer, and provides a 3,13-position substituted berberine derivative, the drug itself has less toxicity and does not affect the growth of normal human cells, and has a good application prospect in the development of novel antitumor drugs, especially in the development of anti-digestive tract tumor drugs.
Owner:HEFEI JUNYIDA BIOMEDICAL TECHNOLOGY CO LTD

Human cell population comprising human retinal progenitor cells without an ISL1 gene for transplantation and methods of use thereof

An object of the present invention is to provide a cell population suitable for transplant of retinal tissue and a method of production thereof. The present invention provides a cell population for transplant, comprising retinal cells with a modified bipolar cell-regulating gene and a method of production thereof.
Owner:RACTHERA CO LTD +1

Recombinant collagen, expression method and use thereof

Provided are a recombinant collagen, an expression method and use thereof. In the present disclosure, the recombinant collagen is expressed by a human embryonic kidney cell Expi293F at a high protein expression level, thereby realizing the expression of a large-molecular-weight recombinant collagen. Activity studies have showed that the expressed recombinant collagen has desirable activity in promoting cell migration, while the recombinant collagen III+I with a fusion tag shows high stability at 4° C. In addition, cell activity studies have shown that the recombinant type III collagen expressed by human cells has better activity in promoting the cell migration than that of a commercially available type III collagen. These results indicate that the human cell expression system is conducive to the expression of highly active and large-molecular-weight recombinant collagen.
Owner:SHANDONG D-NUTRIMEC BIOMEDICAL CO LTD

Hybrid exosome and use thereof

The present invention relates to a hybrid exosome formed by the fusion of a human cell-derived exosome and an artificial exosome. When an active ingredient labeled with a fluorescent material was attached or encapsulated in the hybrid exosome of the present invention and applied to cells, the active ingredient was observed in the cells. In addition, when the exosome was applied to skin tissue, fluorescence expression could also be observed in the dermal layer. Therefore, the hybrid exosome according to the present invention can be used as a novel drug delivery system.
Owner:PUSAN NAT UNIV IND UNIV COOPERATION FOUND +1

Genetically modified mice comprising humanized cellular immune system components with improved diversity of TCRB repertoire

Disclosed herein are non-human animals (e.g., rodents, e.g., mice or rats) genetically engineered to express a human or humanized T cell receptor (TCR) from a human or humanized TCR locus comprising a non-human TCR non-coding sequence, and optionally a humanized T cell co-receptor (e.g., humanized CD4 and / or CD8 (e.g., CD8α and / or CD8β)), and / or a human or humanized major histocompatibility complex that binds the humanized T cell co-receptor (e.g., human or humanized MHC II (e.g., MHC II α and / or MHC II β chains) and / or MHC I (e.g., MHC Iα) respectively, and optionally human or humanized β2 microglobulin). Also provided are embryos, tissues, and cells expressing the same. Methods for making the genetically engineered animals are also provided. Methods for using the genetically engineered animals for developing human therapeutics are also provided.
Owner:REGENERON PHARMACEUTICALS INC

Engineering modified ultra-compact CRISPR / Cas12j-8 and application thereof

The invention belongs to the technical field of molecular biology, and particularly relates to an engineered ultra-compact CRISPR / Cas12j-8 and application thereof. The technical problem to be solved by the invention is that the editing efficiency of a CRISPR / Cas12j-8 system is relatively low. According to the technical scheme, the ultra-compact CRISPR / Cas12j-8 is engineered and transformed, and the nucleotide sequence of the CRISPR / Cas12j-8 is shown as SEQ ID No. 3 or SEQ ID No. 5. According to the present invention, the engineering modification is performed on the crRNA and the Cas12j-8 protein, the en4Cas2j-8 / crRNA-Rz genome editing system is developed, and the system has strong editing activity in soybean, rice and human HEK293T cells, and can edit the target site which cannot be edited previously.
Owner:INNER MONGOLIA UNIVERSITY

Microbial and human cell-free DNA biomarkers for diagnosing and assessing the severity of inflammatory bowel disease

Disclosed herein in some embodiments are methods, compositions, and systems for distinguishing between ulcerative colitis (UC), Crohn's disease (CD) and other Inflammatory Bowel Disorders (IBD) by sequencing cell free nucleic acids. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether UC, CD, or other IBD are asymptomatic, in remission, or active. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether an active form of UC, CD, or other IBD is mild, moderate, or severe.
Owner:KARIUS INC

Application of zinc pyrithione in preparation of NLRP3 inflammasome inhibitor

The invention belongs to the technical field of biological medicine, and particularly relates to application of zinc pyrithione in inhibition of NLRP3 inflammasome activation. The technical problem to be solved by the invention is to provide a new choice for treatment of NLRP3 inflammasome related diseases. The technical scheme of the invention is application of zinc pyrithione in preparation of an NLRP3 inflammasome inhibitor. The invention finds that the zinc pyrithione can inhibit the activation of NLRP3 inflammasomes, and shows a good inhibition effect in mouse and human cells; zinc pyrithione is expected to become a candidate drug for treating NLRP3 inflammasome related diseases.
Owner:THE FIRST AFFILIATED HOSPITAL OF BENGBU MEDICAL COLLEGE

Materials and methods for treatment of usher syndrome type 2A

The present application provides materials and methods for treating a patient with Usher Syndrome Type 2A, both ex vivo and in vivo; materials and methods for editing a USH2A gene in a human cell; materials and methods for editing an USH2A gene containing an IVS40 mutation; materials and methods for treating a patient with an USH2A gene containing an IVS40 mutation; and a method for deleting a sequence comprising an IVS40 mutation within a USH2A gene of a cell. The present application also provides one or more gRNAs or sgRNAs for editing an USH2A gene containing an IVS40 mutation. The present application provides a therapeutic for treating a patient with Usher Syndrome Type 2A. The present application also provides a kit for treating a patient with Usher Syndrome Type 2A.
Owner:CRISPR THERAPEUTICS AG +1